Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-PD-1 Antibody in Combination With Low-dose Decitabine in Relapsed or Refractory Malignancies: an Open-label Phase I/II Trial

Next Previous
X
Search
Trial Profile

Anti-PD-1 Antibody in Combination With Low-dose Decitabine in Relapsed or Refractory Malignancies: an Open-label Phase I/II Trial

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Decitabine
  • Indications Breast cancer; Gastrointestinal cancer; Hodgkin's disease; Liver cancer; Lung cancer; Lymphoma; Non-Hodgkin's lymphoma; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 11 Mar 2021 New trial record
    • 05 Mar 2021 Results (n=51) assessing evaluation of putative biomarkers of response to decitabine-plus-camrelizumab in relapsed/refractory cHL, published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top